Overview
- Editors:
-
-
Benjamin Bonavida
-
Molecular Genetics, University of California, Los Angeles Dept. Microbiology, Immunology &, Los Angeles, USA
- Summarizes common and unique features of mAbs against various cancers
- Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs
- Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (10 chapters)
-
Front Matter
Pages i-xiii
-
- Lina Reslan, Charles Dumontet
Pages 1-24
-
- Yangyang Wang, Francesco Sabbatino, Ling Yu, Elvira Favoino, Xinhui Wang, Matteo Ligorio et al.
Pages 25-47
-
- Emily L. Williams, Sean H. Lim, Stephen A. Beers, Peter W. Johnson, Jonathan C. Strefford, Martin J. Glennie et al.
Pages 49-71
-
- Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman
Pages 73-92
-
-
- Zacharenia Saridaki, John Souglakos
Pages 125-141
-
- Peter Hersey, Stuart Gallagher, Branka Mijatov
Pages 143-155
-
-
-
- Penelope M. Drake, David Rabuka
Pages 183-200
-
Back Matter
Pages 201-202
About this book
​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Editors and Affiliations
-
Molecular Genetics, University of California, Los Angeles Dept. Microbiology, Immunology &, Los Angeles, USA
Benjamin Bonavida
About the editor
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
